Form 4: Director David Sidransky Granted CSBR Stock Options

Champions Oncology Director David Sidransky was granted 21,216 stock options with an exercise price of $6.8, vesting over 12 months starting November 5, 2025.

Summary

• Director David Sidransky of Champions Oncology, Inc. (CSBR) was granted 21,216 options to purchase common stock.
• The options have an exercise price of $6.8 per share.
• The earliest transaction date for these options is November 5, 2025.
• The options vest over a twelve-month period, with specific vesting dates on November 5, 2025, February 5, 2026, May 5, 2026, and August 5, 2026.
• The options are exercisable over a ten-year period, expiring on November 5, 2035.
• Following this transaction, David Sidransky beneficially owns 21,216 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, aligning interests and incentivizing long-term performance. It reflects confidence in the company's future, though the specific value depends on future stock performance.

Positives

• Granting of stock options to a director aligns management incentives with shareholder interests, encouraging long-term value creation.
• The options have a 10-year exercise period, providing a long runway for potential appreciation.

Negatives

• The exercise price of $6.8 indicates the stock needs to trade above this level for the options to have intrinsic value.
• The vesting schedule means the director must remain with the company for at least 12 months to fully realize the grant.

Future Outlook

The grant of future-vesting options suggests an expectation of continued service from the director and potential future stock price appreciation.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and oncology sectors, aiming to incentivize long-term performance and retention in a competitive industry.

Comparison to Industry Standards

• The grant of 21,216 options to a director is a standard practice for aligning interests, comparable to similar grants seen at companies like Guardant Health (GH) or Exact Sciences (EXAS) for their non-executive directors, though the specific number and exercise price would vary based on company size and compensation philosophy.
• A 10-year exercise period is typical for employee and director stock options across many industries, including biotech, providing ample time for value realization.
• A 12-month vesting schedule, with quarterly vesting, is also a common structure, designed to retain talent over a reasonable period.

Stakeholder Impact

• Shareholders: Potential dilution if options are exercised, but also potential for increased long-term value if director incentives lead to improved company performance.
• Employees: May signal stability in leadership and a commitment to equity-based compensation.

Next Steps

• The options will vest on specific dates: February 5, 2026, May 5, 2026, and August 5, 2026.
• The director may choose to exercise these options at any point after vesting and before the expiration date of November 5, 2035.

Key Dates

Recommendation

The grant of stock options to a director is a routine compensation event and does not, by itself, provide sufficient new information to warrant a change in investment recommendation. It aligns the director's interests with shareholders over the long term, which is generally positive, but does not indicate immediate catalysts for significant price movement.

Keywords

Champions Oncology, CSBR, David Sidransky, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Insider Transaction